



Monaldi Archives for Chest Disease

eISSN 2532-5264

<https://www.monaldi-archives.org/>

Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. The **Early Access** service lets users access peer-reviewed articles well before print / regular issue publication, significantly reducing the time it takes for critical findings to reach the research community. These articles are searchable and citable by their DOI (Digital Object Identifier).

The **Monaldi Archives for Chest Disease** is, therefore, e-publishing PDF files of an early version of manuscripts that have undergone a regular peer review and have been accepted for publication, but have not been through the typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one.

The final version of the manuscript will then appear in a regular issue of the journal.

E-publishing of this PDF file has been approved by the authors.

All legal disclaimers applicable to the journal apply to this production process as well.

Monaldi Arch Chest Dis 2024 [Online ahead of print]

To cite this Article:

Ashraf H, Ashfaq H. **Electronic cigarettes: a harm reduction option for smokers?.**
Monaldi Arch Chest Dis doi: 10.4081/monaldi.2024.2965

 ©The Author(s), 2024
Licensee [PAGEPress](#), Italy

Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.



Electronic cigarettes: a harm reduction option for smokers?

Hamza Ashraf, Haider Ashfaq

Department of Medicine, Allama Iqbal Medical College, Lahore, Punjab, Pakistan

Correspondence: Hamza Ashraf, Department of Medicine, Allama Iqbal Medical College, 54770 Lahore, Punjab, Pakistan.

Tel.: +923310282811.

E-mail: monsterguzura@gmail.com

Key words: electronic cigarette, nicotine, tobacco, ENDS, cigarette.

Contributions: HamA, conceptualization and visualization; both authors contribute to data curation, writing of the original draft, review and editing.

Conflict of interest: the authors declare no potential conflict of interest.

Ethics approval and consent to participate: no approval was required as this study is solely based on the author's observations, and literature review and does not involve human subjects.

Patient consent for publication: not applicable.

Funding: none.

Availability of data and materials: data available from the corresponding author upon request.

Dear Editor,

An electronic cigarette (EC) or electronic nicotine delivery system (ENDS) is a tobacco-free device powered by a battery. It usually contains a solution of nicotine, flavorings, and various chemicals, some of which may carry potential risks. The amount of nicotine in an individual EC can vary, ranging from zero to as high as 50 mg/ml. However, it is important to note that some countries, such as the US and Canada, have imposed bans on the maximum concentration of nicotine in e-liquids, limiting it to 20mg/ml. ECs are grouped by generations: first-generation as cig-a-likes which closely resemble traditional cigarettes and are disposable or non-rechargeable, second-generation as tank models or 'vape pens' which feature refillable tanks and rechargeable batteries, and third-generation as adjustable power tank models. Newer fourth generation 'pod' devices like Juul use nicotine salt formulations for higher concentrations and have a compact design. These are most commonly used devices nowadays. [1] (Figure 1). ECs are believed to aid in smoking cessation. E-cigarette aerosols have fewer damaging toxins related to the thousands of toxic compounds in tobacco smoke. The production of carcinogenic substances is unmistakably reduced by the lack of combustion in e-cigarettes. The severity of the respiratory and cardiovascular damage also seems to be less noticeable with ECs than with the regular tobacco cigarettes [2].

Cigarette smoke delivers nicotine by combusting tobacco and has been found to be 33% more harmful than using ECs [3]. EC aerosols contain approximately 80 chemicals [4], whereas cigarette smoke contains around 7000 chemicals and 70 carcinogens [5]. EC comes with some distinct potential risks in contrast to cigarette smoking, including the possibility of fractures, burns, and bleeding due to battery bursts. The leakage of e-liquid can result in contact dermatitis, rashes, and allergic reactions. Alarmingly, there have been reports of e-liquid misuse in suicidal attempts through injection or oral ingestion. Moreover, the attractive taste of ECs has led to their widespread use indoors. Users of EC have reported higher usage of sleep medication compared to combustible cigarette users [6]. The combination of high wattage, elevated nicotine levels (up to 50 mg/ml: while a cigarette contains 20mg/mL of nicotine) [7], and low coil resistance in ECs may lead to increased nicotine exposure compared to tobacco cigarettes [6]. Acute effects of e-cigarette aerosol with nicotine include a significant increase in heart rate, increase in blood pressure, and arterial stiffness. It also causes a sudden increase in flow resistance, indicating obstruction of the conducting airways. Increased arterial stiffness is a blood pressure-independent risk factor for cardiovascular events such as myocardial infarctions and stroke [8]. Butt et al., in a recent study, described a wide spectrum of histopathological findings seen in e-cigarette or vaping product use-

associated lung injury (EVALI), including acute fibrinous pneumonitis, diffuse alveolar damage, or organizing pneumonia, usually bronchiolocentric and accompanied by bronchiolitis [9]. Recent literature has also reported a strong correlation between the use of ECs and the development of pulmonary injury, thereby giving rise to respiratory symptoms and COPD. Thus, chronic usage may lead to long-term adverse health effects [10,11].

Electronic cigarette liquids come in both nicotine and nicotine-free variants. Among the chemicals in ECs, nicotine is the most addictive [12]. Hence, nicotine-free ECs are much less addictive. A systematic review of 78 studies, involving over 22,000 participants, provides strong evidence that ECs with nicotine are more effective for smoking cessation compared to both nicotine-free ECs and nicotine replacement therapy (NRT). For every 100 individuals using nicotine ECs to quit smoking, around 10 to 11 individuals succeed, whereas only six out of 100 using NRT or nicotine-free ECs achieve the same outcome [1]. However, the involvement of nicotine in tumor promotion and progression with antiapoptotic and indirect mitogenic properties has also been reported [13]. In four cross-sectional surveys conducted in Connecticut in 2014, a considerable percentage of youth (34.1%) were unaware of the nicotine concentration in their ECs [14]. Also, nicotine was detected in certain products that were marketed as nicotine-free [12].

While ECs have been promoted as a potential harm reduction tool for smokers looking to quit, it is essential to recognize that they are not without health consequences. Based on the available evidence and the lack of knowledge about the long-term effects of e-cigarettes on respiratory health, the Global Initiative for Obstructive Lung Disease (GOLD) also revised its stance on the possibility that e-cigarettes may help as a bridge for smoking cessation, and GOLD 2024 does not recommend this intervention for smoking cessation in patients with COPD as it can worsen the progression of the disease [15]. The American Heart Association (AHA) and the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) share concerns about the rise in EC use, particularly among young non-smokers. While the AHA acknowledges that ECs might serve as a harm reduction tool for smokers [16], both societies prioritize the potential dangers of initiation in non-smokers. SEPAR advocates the use of proven and effective treatments for smoking cessation, such as varenicline, NRT, bupropion, and psychological counseling, over ECs [17]. This suggests a need to establish clear, careful and balanced policies that consider both harm reduction for current smokers and the prevention of initiation in non-smokers.

While experimental human studies show that ECs have acute cardiovascular effects consistent with stimulants, the long-term effects of ECs are not well understood because they haven't been used long enough to observe chronic impacts. Most EC users are former or current smokers,

complicating causation. Therefore, conclusions on the long-term effects of use of ECs are currently unavailable. More longitudinal, methodologically sound studies are needed to understand the potential long-term impacts of EC use [18]. The popularity of ECs among youth, coupled with limited awareness of nicotine content, underscores the need for targeted education and rigorous oversight. Enforcing legislation to protect passive smokers from e-cigarette aerosols is of the utmost importance [2]. Additional clinical and animal exposure model research is critically needed as the use of EC products continues to grow. To work towards a smoking-free world, we should prioritize evidence-based tobacco control policies, effective cessation programs, and comprehensive public awareness campaigns [16].

References

1. Hartmann-Boyce J, Lindson N, Butler AR, et al. Electronic cigarettes for smoking cessation. *Cochrane Database Syst Rev* 2022;11:CD010216.
2. Yayan J, Franke KJ, Biancosino C, Rasche K. Comparative systematic review on the safety of e-cigarettes and conventional cigarettes. *Food Chem Toxicol* 2024;185:114507.
3. Wilson N, Summers JA, Ait Ouakrim D, et al. Improving on estimates of the potential relative harm to health from using modern ENDS (vaping) compared to tobacco smoking. *BMC Public Health* 2022;21:2038. Erratum in: *BMC Public Health* 2022;22:1788.
4. Thiri3n-Romero I, P3rez-Padilla R, Zabert G, Barrientos-Guti3rrez I. Respiratory impact of electronic cigarettes and "low-risk" tobacco. *Rev Invest Clin* 2019;71:17-27.
5. Centers for Disease Control and Prevention. Overview of chemicals in cigarette smoke. Available from: <https://www.cdc.gov/environmental-exposure-report/about/overview-of-chemicals-in-cigarette-smoke.html>.
6. Brett EI, Miller MB, Leavens ELS, et al. Electronic cigarette use and sleep health in young adults. *J Sleep Res* 2020;29:e12902.
7. Goenka S, Simon SR. Effects of e-cigarette refill liquid flavorings with and without nicotine on human retinal pigment epithelial cells: a preliminary study. *Int J Environ Res Public Health* 2021;18:11655.
8. Antoniewicz L, Brynedal A, Hedman L, et al. Acute effects of electronic cigarette inhalation on the vasculature and the conducting airways. *Cardiovasc Toxicol* 2019;19:441-50.
9. Butt YM, Smith ML, Tazelaar HD, et al. Pathology of vaping-associated lung injury. *N Engl J Med* 2019;381:1780-1.
10. Song B, Li H, Zhang H, et al. Impact of electronic cigarette usage on the onset of respiratory

symptoms and COPD among Chinese adults. *Sci Rep* 2024;14:5598.

11. Bhatta DN, Glantz SA. Association of e-cigarette use with respiratory disease among adults: a longitudinal analysis. *Am J Prev Med* 2020;58:182-90.

12. Qasim H, Karim ZA, Rivera JO, et al. Impact of electronic cigarettes on the cardiovascular system. *J Am Heart Assoc* 2017;6:e006353.

13. Tonini G, D'Onofrio L, Dell'Aquila E, Pezzuto A. New molecular insights in tobacco-induced lung cancer. *Future Oncol* 2013;9:649-55.

14. Morean ME, Kong G, Cavallo DA, et al. Nicotine concentration of e-cigarettes used by adolescents. *Drug Alcohol Depend* 2016;167:224-7.

15. Agusti A, Vogelmeier CF. GOLD 2024: a brief overview of key changes. *J Bras Pneumol* 2023;49:e20230369.

16. Rose JJ, Krishnan-Sarin S, Exil VJ, et al. Cardiopulmonary impact of electronic cigarettes and vaping products: a scientific statement from the American Heart Association. *Circulation* 2023;148:703-28.

17. Signes-Costa J, de Granda-Orive JJ, Ramos Pinedo Á, et al. Official statement of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) on electronic cigarettes and IQOS®. *Arch Bronconeumol (Engl Ed)* 2019;55:581-6.

18. Bals R, Boyd J, Esposito S, et al. Electronic cigarettes: a task force report from the European Respiratory Society. *Eur Respir J* 2019;53:1801151.

The Evolution of E-Cigarette, or Vaping, Products



Figure 1. The evolution of e-cigarette.